Cigna (CI) Q3 2026 Earnings
Adjusted EPS excludes after-tax amortization of acquired intangible assets of $449 million ($1.71/share), special items of $146 million (strategic optimization program $62 million, litigation charges $49 million, integration and transaction-related costs $17 million, deferred tax expenses $18 million), and net investment losses of $67 million ($0.25/share). GAAP EPS was $5.47.
How Did CI Stock React to Q3 2026 Earnings?
Did CI Beat Earnings? Q3 2026 Results
Yes. Cigna reported Q3 2026 earnings of $7.98 a share on Nov 5, 2026, beating the $7.51 consensus estimate by 6.3%. Revenue was $73.7B against a $72.4B estimate.
The Cigna Group delivered a broad beat in its third quarter of 2026, extending its run of consensus-topping results to five consecutive quarters as adjusted EPS of $7.98 cleared the $7.51 consensus estimate by 6.30% and revenue of $73.68 billion edged 1.70% above expectations on 5.6% year-over-year growth. The headline driver was a 15% jump in pre-tax adjusted income at Cigna Healthcare to $1.19 billion, powered by premium rate increases and higher net investment income, while Specialty and Care Services within Evernorth contributed a 15% profit gain on biosimilar and specialty generic adoption. Those gains partly offset a 22% decline in Pharmacy Benefit Services adjusted income tied to large client contract renewals. GAAP earnings fell to $1.44 billion from $1.87 billion a year earlier, primarily reflecting the absence of a prior-year gain on sale. Management raised full-year 2026 adjusted EPS guidance by $0.15 to at least $30.60 per share, while unveiling a $3 billion multi-year modernization initiative and long-term targets of 10% to 14% adjusted EPS growth through 2030, signals of confidence even as the broader managed-care sector navigates structural transformation.
- Total revenues up 6% driven by growth in both Evernorth Health Services and Cigna Healthcare
- Pharmacy Benefit Services adjusted revenues up 9% primarily due to drug mix
- Specialty and Care Services pre-tax adjusted income up 15% on strong organic growth in specialty businesses, including higher biosimilar and specialty generic adoption
- Strong specialty distribution revenue growth, partially offset by lower specialty pharmacy revenue
- Cigna Healthcare adjusted revenues up 9% on premium rate increases
- Cigna Healthcare pre-tax adjusted income up 15% on higher net investment income and improved operating efficiency
- Pharmacy Benefit Services pre-tax adjusted income down 22% due to large client contract renewals and strategic investments
- Medical customers up 2% from year-end 2025 on growth in Middle and Select markets
- Favorable prior year reserve development of $356 million for the nine months ended September 30, 2026
“Our vision for The Cigna Group's next chapter of profitable growth is grounded in delivering greater value and personalized experiences for our customers, with three priorities: driving core growth, leveraging our distinct capabilities, and executing with discipline.”
Cigna CEO, on the earnings call
What Is Cigna's Outlook?
The Cigna Group raised its full-year 2026 adjusted income from operations outlook by $0.15 to at least $30.60 per share. This includes the impact of expected share repurchases and anticipated dividends. Segment and ratio guidance: - Evernorth pre-tax adjusted income from operations of at least $6,900 million - Cigna Healthcare pre-tax adjusted income from operations of at least $4,600 million, up $50 million - Cigna Healthcare medical care ratio of 84.2% +/- 25 bps, narrowed by 50 bps At its 2026 Investor Day, the company set long-term targets including 10%-14% adjusted EPS CAGR and about $50B in cumulative operating cash flow through 2030. It also announced the multi-year $3B 'Accelerate to One' modernization and productivity initiative.
CI YoY Financials
| Metric | Q3 2026 | Q3 2025 | Year over year |
|---|---|---|---|
| Revenue | $73.7B | $69.7B | +5.6% |
| Net Income | $1.4B | $1.9B | −22.8% |
CI Revenue by Segment
When Does Cigna Report Next?
Figures from SEC filings and company reports. Not investment advice.